Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Novel Therapeutic Strategies for Neuro-Oncology
share announcement

Novel Therapeutic Strategies for Neuro-Oncology

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (15 May 2023) | Viewed by 2975

Special Issue Editors

Dr. Christian F. Freyschlag

E-Mail Website
Guest Editor
Associate Professor, Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria
Interests: neuro-oncological surgery; intraoperative tumor visualization; cell–cell communication
Special Issues, Collections and Topics in MDPI journals
Dr. Astrid E. Grams

E-Mail Website
Guest Editor
Associate Professor, Department of Neuroradiology, Medical University of Innsbruck, Innsbruck, Austria
Interests: metabolic imaging; noninvasive tumor profiling; interventional neuroradiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to this Cancers Special Issue on Novel Therapeutic Strategies for Neuro-Oncology. Within our fast-growing scientific field, we would like to endorse researchers in search of visionary and brave endeavors to submit their work, including specialties of clinical, translational and basic research in neuro-oncology. We welcome manuscripts concerning surgical excellence, promising treatment targets, prognostic and predictive markers, neuroimaging and combinations thereof, including big data research.

With this Special Issue, we aim to promote novel and visionary treatment strategies carried out in clinical pilot projects and basic and translational research. We endorse all specialists involved in neuro-oncology to submit manuscripts. Surgical technique and visualization, imaging (both MR and PET) as well as radiotherapy and medical treatment will be featured in this Special Issue, welcoming original research articles and reviews.

We look forward to receiving your contributions.

You may choose our Joint Special Issue in Current Oncology.

Dr. Christian F. Freyschlag
Dr. Astrid E. Grams
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neuro-oncology
  • neurosurgery
  • radiation therapy
  • neuroimaging
  • glioma
  • glioblastoma
  • brain metastasis
  • translational research
  • cell communication
  • treatment resistance
  • tumor metabolomics
  • combined treatment
  • low-grade gliomas
  • tumor-treating fields

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 1203 KiB  
Article
Age-Dependent Impact of Concomitant Radio-Chemotherapy and MGMT Promotor Methylation on PFS and OS in Patients with IDH Wild-Type Glioblastoma: The Real-Life Data
by Aleksandrs Krigers, Julia Klingenschmid, Tolga Cosar, Patrizia Moser, Claudius Thomé and Christian F. Freyschlag
Cancers 2022, 14(24), 6180; https://doi.org/10.3390/cancers14246180 - 14 Dec 2022
Viewed by 974
Abstract
Biological but not chronological age plus performance have more impact on decision making in glioblastoma patients. We investigated how progression-free survival (PFS) and overall survival (OS) in older patients with IDH wild-type glioblastoma were influenced by concomitant radio-chemotherapy and MGMT promotor methylation status [...] Read more.
Biological but not chronological age plus performance have more impact on decision making in glioblastoma patients. We investigated how progression-free survival (PFS) and overall survival (OS) in older patients with IDH wild-type glioblastoma were influenced by concomitant radio-chemotherapy and MGMT promotor methylation status in real-life settings. In total, 142 out of 273 (52%) evaluated patients were older than 65 years, and 77 (55%) of them received concomitant radio-chemotherapy. In senior patients, the initiation of concomitant radio-chemotherapy was associated with significantly better PFS: 15.3 months (CI95: 11.7–18.9) vs. 7.0 months (CI95: 4.3–9.6; p = 0.002). The favorable influence on PFS was not related to MGMT promotor methylation status as it was in the younger cohort. In seniors, concomitant radio-chemotherapy was related to significantly better OS: 20.0 months (CI95: 14.3–26.7) vs. 4.9 months (CI95: 3.5–6.2), p < 0.001. MGMT promotor methylation was related to a more favorable OS only, if concomitant radio-chemotherapy was initiated. In conclusion, more than half of the glioblastoma cohort was older than 65 years of age. Even if PFS and OS were shorter than in the younger cohort, concomitant radio-chemotherapy provided a survival advantage. In real life, MGMT promotor methylation had a positive impact on OS only if the adjuvant therapy was applied. Full article
(This article belongs to the Special Issue Novel Therapeutic Strategies for Neuro-Oncology)
►▼ Show Figures

Figure 1

Review

Jump to: Research

21 pages, 4416 KiB  
Review
A Multi-Disciplinary Approach to Diagnosis and Treatment of Radionecrosis in Malignant Gliomas and Cerebral Metastases
by Julian Mangesius, Stephanie Mangesius, Matthias Demetz, Christian Uprimny, Gianpaolo Di Santo, Malik Galijasevic, Danijela Minasch, Elke R. Gizewski, Ute Ganswindt, Irene Virgolini, Claudius Thomé, Christian F. Freyschlag and Johannes Kerschbaumer
Cancers 2022, 14(24), 6264; https://doi.org/10.3390/cancers14246264 - 19 Dec 2022
Cited by 4 | Viewed by 1522
Abstract
Radiation necrosis represents a potentially devastating complication after radiation therapy in brain tumors. The establishment of the diagnosis and especially the differentiation from progression and pseudoprogression with its therapeutic implications requires interdisciplinary consent and monitoring. Herein, we want to provide an overview of [...] Read more.
Radiation necrosis represents a potentially devastating complication after radiation therapy in brain tumors. The establishment of the diagnosis and especially the differentiation from progression and pseudoprogression with its therapeutic implications requires interdisciplinary consent and monitoring. Herein, we want to provide an overview of the diagnostic modalities, therapeutic possibilities and an outlook on future developments to tackle this challenging topic. The aim of this report is to provide an overview of the current morphological, functional, metabolic and evolving imaging tools described in the literature in order to (I) identify the best criteria to distinguish radionecrosis from tumor recurrence after the radio-oncological treatment of malignant gliomas and cerebral metastases, (II) analyze the therapeutic possibilities and (III) give an outlook on future developments to tackle this challenging topic. Additionally, we provide the experience of a tertiary tumor center with this important issue in neuro-oncology and provide an institutional pathway dealing with this problem. Full article
(This article belongs to the Special Issue Novel Therapeutic Strategies for Neuro-Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop